These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25645552)

  • 41. Vasopressor administration and sepsis: a survey of Canadian intensivists.
    Lamontagne F; Cook DJ; Adhikari NKJ; Briel M; Duffett M; Kho ME; Burns KEA; Guyatt G; Turgeon AF; Zhou Q; Meade MO
    J Crit Care; 2011 Oct; 26(5):532.e1-532.e7. PubMed ID: 21454040
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials.
    Vasu TS; Cavallazzi R; Hirani A; Kaplan G; Leiby B; Marik PE
    J Intensive Care Med; 2012; 27(3):172-8. PubMed ID: 21436167
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Vasopressin in distributive shock : Brief summary of the guidelines of the Canadian Critical Care Society published in December 2019].
    Bayerl S; Wöhrle T; Kilger E
    Anaesthesist; 2020 Mar; 69(3):159-161. PubMed ID: 32055884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Weapons of pressure resuscitation for septic shock.
    Martin C
    Intensive Care Med; 2003 Oct; 29(10):1621-2. PubMed ID: 12942169
    [No Abstract]   [Full Text] [Related]  

  • 45. Vasopressor for refractory septic shock: dexmedetomidine could help decrease norepinephrine requirements.
    Dargent A; Quintin L; Jacquier M; Fournel I; Quenot JP
    Minerva Anestesiol; 2020 Aug; 86(8):885-886. PubMed ID: 32538581
    [No Abstract]   [Full Text] [Related]  

  • 46. Ascorbate-dependent vasopressor synthesis: a rationale for vitamin C administration in severe sepsis and septic shock?
    Carr AC; Shaw GM; Fowler AA; Natarajan R
    Crit Care; 2015 Nov; 19():418. PubMed ID: 26612352
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Studies in clinical shock and hypotension. 3. Comparative effects of vasopressor drugs and dextran.
    Cohn JN; Luria MH
    Arch Intern Med; 1965 Oct; 116(4):562-6. PubMed ID: 4284276
    [No Abstract]   [Full Text] [Related]  

  • 48. [Problems in the treatment of cardiogenic shock].
    Heublein B; Parsi RA
    Dtsch Gesundheitsw; 1970 Apr; 25(16):732-7. PubMed ID: 4320726
    [No Abstract]   [Full Text] [Related]  

  • 49. Angiotensin-II: more than just another vasoconstrictor to treat septic shock-induced hypotension?*.
    Asfar P; Chawla L; Lerolle N; Radermacher P
    Crit Care Med; 2014 Aug; 42(8):1961-3. PubMed ID: 25029144
    [No Abstract]   [Full Text] [Related]  

  • 50. [Cardiovascular analeptics in respiratory resuscitation].
    Voisin C; Wattel F; Gosselin B; Tonnel AB; Dewailly P
    Anesth Analg (Paris); 1969; 26(5):763-9. PubMed ID: 4391675
    [No Abstract]   [Full Text] [Related]  

  • 51. Norepinephrine administration in septic shock: how much is enough?
    De Backer D; Vincent JL
    Crit Care Med; 2002 Jun; 30(6):1398-9. PubMed ID: 12072710
    [No Abstract]   [Full Text] [Related]  

  • 52. [Vasopressor drugs in shock due to myocardial infarction].
    Adamska-Dyniewska H
    Pol Tyg Lek; 1967 Oct; 22(45):1744-7. PubMed ID: 4294154
    [No Abstract]   [Full Text] [Related]  

  • 53. Less is more: catecholamine-sparing strategies in septic shock.
    Venkatesh B; Khanna AK; Cohen J
    Intensive Care Med; 2019 Dec; 45(12):1810-1812. PubMed ID: 31520103
    [No Abstract]   [Full Text] [Related]  

  • 54. Impact of duration of hypotension prior to norepinephrine initiation in medical intensive care unit patients with septic shock: A prospective observational study.
    Patel JJ; Kurman JS; Biesboer A; Taha H; Katz M; Szabo A; Simpson SQ; Jacobs ER
    J Crit Care; 2017 Aug; 40():178-183. PubMed ID: 28412642
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vasopressin in catecholamine-resistant septic and cardiogenic shock in very-low-birthweight infants.
    Meyer S; Löffler G; Polcher T; Gottschling S; Gortner L
    Acta Paediatr; 2006 Oct; 95(10):1309-12. PubMed ID: 16982509
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of angiotensin II in treatment of refractory distributive shock.
    Rodriguez R; Fernandez EM
    Am J Health Syst Pharm; 2019 Jan; 76(2):101-107. PubMed ID: 31361800
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The authors reply.
    Annane D; Dellinger RP
    Crit Care Med; 2013 Dec; 41(12):e484. PubMed ID: 24275413
    [No Abstract]   [Full Text] [Related]  

  • 58. Refractory septic shock and alternative wordings: A systematic review of literature.
    Antonucci E; Polo T; Giovini M; Girardis M; Martin-Loeches I; Nielsen ND; Lozsán FJC; Ferrer R; Lakbar I; Leone M
    J Crit Care; 2023 Jun; 75():154258. PubMed ID: 36706554
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The ATHOS-3 trial, angiotensin II and The Three Musketeers.
    Bellomo R; Hilton A
    Crit Care Resusc; 2017 Mar; 19(1):3-4. PubMed ID: 28215124
    [No Abstract]   [Full Text] [Related]  

  • 60. Management of Refractory Vasodilatory Shock.
    Jentzer JC; Vallabhajosyula S; Khanna AK; Chawla LS; Busse LW; Kashani KB
    Chest; 2018 Aug; 154(2):416-426. PubMed ID: 29329694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.